Bruker (NASDAQ:BRKR) Sees Strong Trading Volume – What’s Next?

Bruker Co. (NASDAQ:BRKR) saw unusually-strong trading volume on Tuesday . Approximately 903,858 shares were traded during trading, a decline of 12% from the previous session’s volume of 1,028,228 shares.The stock last traded at $64.70 and had previously closed at $63.40.

Analysts Set New Price Targets

A number of equities analysts have commented on BRKR shares. Citigroup reduced their target price on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. The Goldman Sachs Group dropped their price objective on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. TD Cowen dropped their price objective on shares of Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a report on Wednesday, August 7th. Finally, Wells Fargo & Company started coverage on shares of Bruker in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price target for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.82.

Bruker Stock Down 0.4 %

The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $9.18 billion, a price-to-earnings ratio of 23.05, a PEG ratio of 2.52 and a beta of 1.18. The firm’s 50 day simple moving average is $65.11 and its 200-day simple moving average is $69.71.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.52. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business had revenue of $800.70 million for the quarter, compared to analysts’ expectations of $799.44 million. During the same period in the prior year, the company posted $0.50 EPS. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. On average, sell-side analysts anticipate that Bruker Co. will post 2.61 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Monday, September 2nd were issued a $0.05 dividend. The ex-dividend date was Friday, August 30th. This represents a $0.20 dividend on an annualized basis and a yield of 0.32%. Bruker’s dividend payout ratio (DPR) is 7.27%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Rise Advisors LLC acquired a new stake in Bruker during the 1st quarter worth approximately $27,000. Covestor Ltd lifted its stake in Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after purchasing an additional 210 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 218 shares during the last quarter. UMB Bank n.a. lifted its stake in Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the last quarter. Finally, Gordian Capital Singapore Pte Ltd bought a new stake in shares of Bruker during the second quarter valued at about $52,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.